Molecule Name |
DB00444
|
DrugBank Groups |
Approved
|
Cluster No |
251
|
Smiles |
S1(C(=CC=C1)C8(OC7(C(O)C(O)C(OC5(C2(=C(C=C3(OCOC3(=C2)))C(C4(=CC(OC)=C(O)C(=C4)OC))C6(C5COC6=O))))OC7CO8)))
|
Download |
mol2, pdbqt
|
TPSA |
189,07
|
Non-H Atoms |
46
|
Non-C/H Atoms |
14
|
Metal-Atoms |
0
|
Electronegative Atoms |
14
|
Stereo Centers |
10
|
Rotatable Bonds |
6
|
Rings Closures |
8
|
Small Rings |
8
|
Aromatic Rings |
3
|
Aromatic Atoms |
17
|
sp3-Atoms |
27
|
Symmetric atoms |
4
|
cLogS |
-4,852
|
MW |
656,659
|
cLogP |
1,3462
|
HBA |
13
|
HBD |
3
|
Ro5 violations |
2
|
Druglikeness |
-0,10951
|
DrugScore |
0,316335911233779
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Blood-Brain Barrier |
BBB-
|
Human Intestinal Absorption |
HIA+
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-3,1987
|
Caco-2 Permeability 2 |
0,2995
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
AMES Toxicity |
AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
0,7111
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,6516
|
Honey Bee Toxicity |
High HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,8354
|
Carcinogenicity (Three-class) |
Non-required
|